ArticleFrontiers in pharmacology2025
Cost-utility analysis of PCSK9 inhibitors for hypercholesterolemia: a Chinese healthcare perspective.
Dandan Hu et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
1 paper cites it
this papercites it